Thursday, August 05, 2021

Surgical Site Infections in Obs & Gynae

The points in this post have been extracted from a TOG article published in April 2021. Surgical site infection poses a challenge for surgery and has huge impact on patient care/safety and healthcare system. It is an important cause of patient morbidity and if severe can even lead to death. 

Different guidelines have been produced to address this issue. This article provides a very good resource of comprehensive information about SSI. 

It is recommended to read the original article to grasp the topic completely. 

I hope you find this post helpful. 

Suggestions to improve future posts are welcome.

Thanks


Surgical Site Infections
https://www.rubabk4courses.com/courses/


Introduction

  • SSI remains a peri-surgical problem
  • May lead to severe morbidity & mortality, prolonged hospitalisation & enormous economic costs

Measure to reduce SSI

  • Improved ventilation in OTs
  • Equipment sterilisation
  • Barrier use during surgery

Factors which increase SSI

  • Antibiotic resistant pathogens, chronic disorders like DM, alcoholism, obesity & immunosuppression
  • In obstetrics SSI associated with prolonged labour, emergency CS & multiple vaginal examinations
  • Common pathogens include gram +ve & -ve organisms such as Staphylococcus aureus & E. Coli

Definition

  • Infection of superficial or deep skin incision, or of an organ or space, occurring up to 30 days after surgery if no implant was left behind, or within 1 year if an implant was left in place

Specific Criteria for diagnosis

Superficial wound infection at least one of the following

  • Purulent effluent or exudate with organisms identified
  • One of following: pain, redness, localized swelling, tenderness or heat
  • Diagnosis by surgeon or attending physician

Deep wound infection at least one of the following

  • Purulent exudate from deep wound incision
  • Spontaneous dehiscence of deep incisional wound or if deliberately opened with temp >30˚C, localized pain or tenderness
  • Abscess or infection involving deep wound incisions
  • Diagnosis by surgeon or attending physician

Organ or space infection at least one of the following

  • Purulent exudate from a drain
  • Organism isolated
  • Evidence of abscess or infection
  • Diagnosis by surgeon or attending physician

Wound Classification

Ref: TOG

Epidemiology

  • Incidence 2-6% of surgeries in high-income countries
  • UK in 2006 survey
    • Incidence of health care-acquired infection 8% out of which 14% were SSI 
    • 5% patients having surgery had SSI
  • Incidence varies according to the type of surgery
    • Highest after bowel surgery 8%
    • Lowest after knee replacement 0.5%
    • After TAH 1.6%
    • After CS 3-15%

Risk factors  

Continue Reading

Friday, June 25, 2021

Epilepsy in Pregnancy

Here is video from our recently completed MRCOG Part 2 Course.

This is an extract and covers the Epilepsy in Pregnancy.

Feel free to leave your feedback.

For Further information


Saturday, April 03, 2021

Cancer Survival Rates

This is a quick post about one a very important frequently tested fact in the exam i.e. five year survival rates of different stages of gynaecology cancers. Recently there have been questions for the one year survival rates as well. I have compiled the rates in the form of tables for quick review.

I hope this is helpful.

Visit cancer research UK for updated information Click Here




Cervical Cancer


Overall 5 year survival 60%

Overall 1 year survival 80%


Stage

5 Yr Survival 

1 Yr Survival 

I

79%

96%

II

47%

92%

III

22%

75%

IV

7%

50%


Endometrial Cancer


Overall 5 year survival 77%

Overall 1 year survival 89%


Stage

5 Yr Survival

1 Yr Survival

I

76%

99%

II

56%

95%

III

30%

83%

IV

10%

46%


Ovarian Cancer


Overall 5 year survival 43%

Overall 1 year survival 72%


Stage

5 Yr Survival

1 Yr Survival

I

93%

98%

II

67%

89%

III

27%

73%

IV

13%

53%


Vulval Cancer


Overall 5 year survival 65%

Overall 1 year survival 86%


Stage

5 Yr Survival

1 Yr Survival

I

86%

96%

II

74%

89%

III

54%

78%

IV

15%

43%


According to groin node status 5 yrs survival

Groin Node Negative

92%

ipsilateral

75%

bilateral

30%

>2 nodes

25%

>6 nodes

0%


You may also like

Module 17: Gynaecology Oncology

CA-125

Lynch Syndrome

Thursday, April 01, 2021

Lynch Syndrome

This post is about one of an important condition, we come across in gynaecology oncology and that is Lynch Syndrome. Recently there has been evidence found for it to be strongly associated with endometrial and ovarian cancer. NICE recommends to screen all women with endometrial cancer for Lynch syndrome. The points are taken from a recently published TOG which is free access.

To download the original article: Click Here

For infographic: Click Here



Introduction

  • Lynch syndrome (LS) → an autosomal dominant inherited condition
  • Predisposes to cancers which include colorectal, endometrial & ovarian
  • Most affected 95% people are unaware of their risk
  • Gynecological cancer → often the first cancer diagnosis in women

Epidemiology

  • Exact prevalence → unclear 1:278 to 1:440
  • LS is the most common inherited cancer predisposition syndrome 
  • Around 3% endometrial cancers are due to LS prognosis very good 10-yr survival ≥90%
  • Association with ovarian cancer less clear 1-2%
  • NICE recommends universal screening of individuals with colorectal cancer and endometrial cancer
  • Degree of penetrance, disease spectrum and age of cancer onset variable

Lynch Syndrome

  • Arises from inherited mutations in genes encoding proteins of highly conserved DNA mismatch repair (MMR) system MLH1, MSH2, MSH6 & PMS2
  • MMR system maintains genomic stability
  • Without functioning MMR→ uncorrected mutation rate ↑ by 1000-fold

How does it happen?

  • One pathogenic allele of an MMR gene is inherited & once second allele acquires somatic inactivating mutation→ as MMR system is non-functional which leads to widespread genomic instability as errors which occur during replication can not be corrected
  • Hypermutation leads to carcinogenesis
  • Incidence of endometrial cancer in (MSH6 = MLH1 & MLH2) > PMS2
Continue Reading

Monday, March 29, 2021

Raised CA 125

This blog post covers important points about CA125 which are taken from a recently published TOG article in January 2021. CA125 has been used as a tumor marker for ovarian cancer but with some limitations. 

I hope this quick post is helpful. 

Feel free to leave your feedback in comments and suggestions to improve future posts are welcome.

Thanks


Elevated CA125 TOG 2021


Introduction

  • Leading cause of death from any gynae malignancy → Ovarian Cancer
  • Over 70% present with late stage disease (Stage III or IV)
  • Normal Level CA 125→ <35 IU/ml
  • Level can increase in both physiological or pathological conditions
  • CA125 expressed in tissues derived from embryonic coelomic epithelia which includes endometrium, mullerian epithelium, peritoneum, pleura & pericardium
  • CA125 has role in cell-mediated immunity
  • Antigen is not produced directly by tumour & not a tumour marker per se

CA125 & mechanical stress

  • Highest levels of CA125 seen in ascites associated with ovarian cancer
  • CA125 correlates positively with ascites volume
  • Levels are much higher in ascitic fluid than blood levels which shows that antigen originates in ascitic fluid rather than tumour itself

Ovarian Cancer & CA125

Use in Diagnosis

  • CA125 increased in epithelial ovarian cancers & less commonly in non-epithelial
  • Used with TVS to calculate RMI which guides further management
  • If RMI >250 iu/ml → Refer to Cancer Centre
  • 50% with stage I & occult cancers have normal levels

Use in follow-up

  • After surgical resection→ serum levels fall by half within 10 days
Continue Reading